Kisspeptin

What it is

Kisspeptin is a peptide hormone family encoded by the KISS1 gene that serves as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. The original peptide was isolated in 1996 and named after Hershey, Pennsylvania (where it was discovered), with the name referencing “Hershey’s Kisses.” Multiple active forms exist; the most clinically relevant are kisspeptin-54, kisspeptin-10, and kisspeptin-13.

The discovery of kisspeptin’s central role in reproductive endocrinology in the early 2000s fundamentally changed understanding of how puberty initiates and how reproductive function is regulated. Mutations in the KISS1 receptor (KISS1R, also called GPR54) cause hypogonadotropic hypogonadism in humans, demonstrating the essential role of kisspeptin signaling.

Kisspeptin is not FDA-approved for any indication. Clinical use is in research settings and through licensed compounding pharmacies for select applications. The peptide represents an emerging therapeutic with strong physiological rationale but limited large-scale clinical trial validation for the use cases it is currently being applied to.

Mechanism of action

Kisspeptin acts as the upstream driver of the HPG axis:

• Hypothalamic kisspeptin neurons: two main populations of kisspeptin-producing neurons in the hypothalamus (in the arcuate nucleus and the AVPV/RP3V regions) drive pulsatile GnRH release. The arcuate population is responsible for the basal pulsatile release pattern; the AVPV population is responsible for the preovulatory LH surge in females.
• GnRH release: kisspeptin neurons synapse on GnRH neurons in the hypothalamus and stimulate pulsatile GnRH release into the hypothalamo-hypophyseal portal system.
• Downstream HPG axis activation: GnRH stimulates pituitary LH and FSH release, which in turn drives gonadal hormone production (testosterone in males, estrogen and progesterone in females) and gametogenesis.
• Feedback responsive: kisspeptin neurons integrate negative and positive feedback signals from sex steroids, allowing physiologic regulation of reproductive function.
• Sexual desire effects: kisspeptin appears to have direct effects on sexual desire and arousal pathways beyond its endocrine effects, possibly through CNS receptors in regions involved in sexual response.

Research findings

The clinical research base on therapeutic kisspeptin is growing but limited:

Hypothalamic amenorrhea: studies have demonstrated that kisspeptin can restore LH/FSH pulsatility in women with hypothalamic amenorrhea, including conditions like exercise-induced amenorrhea and stress-related HPA suppression of HPG function.

IVF triggering: kisspeptin has been studied as an alternative to hCG for triggering ovulation in IVF cycles. Some research suggests reduced ovarian hyperstimulation risk compared to hCG triggering.

Male hypogonadism: some research on kisspeptin in select male hypogonadism scenarios, particularly hypothalamic causes.

Sexual desire: recent studies including work from Imperial College London (Jayasena and colleagues) have explored kisspeptin’s effects on sexual desire and arousal in both men and women, with some encouraging findings on subjective measures and brain activation patterns.

Most clinical use to date has been in research settings; routine clinical practice use is limited and emerging.

How we use it at The Tide

We prescribe kisspeptin selectively in carefully evaluated scenarios:

• Patients with documented HPG axis suppression contributing to low libido, after appropriate endocrine workup
• Patients with certain hypothalamic causes of low sex hormone levels where conventional approaches have been inadequate
• Patients exploring kisspeptin’s effects on sexual desire after standard interventions (hormonal optimization, addressing relational and psychological factors) have been considered

Important boundaries: kisspeptin is not a generic libido enhancer or a fertility treatment we provide outside specific indications. Patients seeking fertility care are referred to reproductive endocrinology. We use kisspeptin in specific scenarios where the physiological rationale aligns with patient need and where appropriate workup has been completed.

Standard dosing: typically administered as subcutaneous injection in cycles of 6–8 weeks. Specific dosing depends on the clinical scenario and is individualized.

What good response looks like: patients with appropriate indication may report changes in sexual desire, energy, or hormonal markers within 4–6 weeks. Clinical evaluation guides ongoing therapy decisions.

Side effects and contraindications

Kisspeptin has been generally well-tolerated in research settings:

• Mild injection site reactions
• Rare flushing or warmth shortly after injection
• Possible effects on menstrual cycle in women (mechanistically expected given the hormonal actions)
• Theoretical possibility of testicular discomfort in men due to LH stimulation effects

Contraindicated in:

• Pregnancy and breastfeeding
• Hormone-sensitive malignancies (breast, prostate)
• Active major mental health conditions where focused care is appropriate
• Patients on hormonal therapy without appropriate coordination of care

What we don’t yet know

The clinical development of kisspeptin therapeutics is still in early phases. Optimal dosing for various indications is largely empirical and based on research dosing rather than large clinical trials. Long-term safety with chronic use has not been formally characterized. The relative effectiveness of kisspeptin vs. other approaches to HPG axis support is not well established in head-to-head studies. The fundamental question of whether kisspeptin therapy is optimal vs. addressing the underlying causes of HPG suppression (which are often lifestyle and stress-related) is important — kisspeptin should not substitute for foundational interventions. We present kisspeptin honestly: an emerging therapeutic with strong physiological rationale, limited but encouraging clinical research, and appropriate selective use in specific scenarios.